MDT - Medtronic plc
| Previous close | 97.50 |
| Open | 97.60 |
| Bid | 97.05 x 1000 |
| Ask | 97.95 x 1000 |
| Day's range | 97.37 - 98.16 |
| 52-week range | 81.66 - 100.15 |
| Volume | 3,056,859 |
| Avg. volume | 5,675,745 |
| Market cap | 130.718B |
| Beta (3Y monthly) | 0.53 |
| PE ratio (TTM) | 28.59 |
| EPS (TTM) | 3.41 |
| Earnings date | 20 Aug 2019 |
| Forward dividend & yield | 2.00 (2.16%) |
| Ex-dividend date | 2019-03-21 |
| 1y target est | 103.17 |
- Zacks•4 days ago
Medtronic Delivers Favorable Outcome on Guardian Connect
Medtronic's (MDT) data indicates that Guardian Connect will enable patients to better understand glucose trends and increase Time in Range.
GlobeNewswire•5 days agoReal-World Data from Guardian(TM) Connect and Sugar.IQ(TM) Reveal Improved Diabetes Outcomes
June 10, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced real-world data on its Guardian(TM) Connect continuous glucose monitoring (CGM) system and Sugar.IQ(TM) diabetes assistant app presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) Annual Meeting in San Francisco. The data presented were recorded by users of the Guardian Connect system paired with Sugar.IQ diabetes assistant, a separate first-of-its-kind intelligent app that continually analyzes how an individual`s glucose levels respond to food intake, insulin dosages, daily routines and other factors1. The Sugar.IQ app combines data from the Guardian Connect system with artificial intelligence technology from Medtronic`s strategic partner, IBM® Watson Health, to detect important patterns and trends for people with diabetes and help them make more informed decisions on how to better manage glucose levels and stay within target range.
- GlobeNewswire•5 days ago
Medtronic Announces Its Forthcoming Robotic Assisted Surgical Platform to Feature Three-Dimensional Vision System from KARL STORZ
Four Year Partnership Made Public Today DUBLIN - June 10, 2019 - To enable upcoming regulatory filings, Medtronic plc (NYSE:MDT) today made public its partnership with KARL STORZ SE & Co. KG (Tuttlingen, ...
- GlobeNewswire•7 days ago
Medtronic Initiates Pivotal Trial for Bluetooth Enabled MiniMed(TM) 780G Advanced Hybrid Closed Loop System Designed to Automate Correction Bolusing
June 8, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced the enrollment of the first study participants in the company`s pivotal trial of its Bluetooth® enabled MiniMed(TM) 780G advanced hybrid closed loop (AHCL) system. This next-generation system is designed to automate the delivery of correction boluses when the user experiences, or is predicted to experience, prolonged high glucose levels based on their sensor readings. The trial will evaluate the safety of the MiniMed 780G system in participants with type 1 diabetes at home, at work, during exercise and other daily activities.
- GlobeNewswire•7 days ago
Medtronic Initiates Pivotal Trial for Next-Generation Guardian(TM) Continuous Glucose Monitoring Sensor
June 8, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced that it has initiated the company`s pivotal trial for its next-generation Guardian(TM) continuous glucose monitoring (CGM) sensor designed to improve accuracy and overall system performance, reduce sensor calibrations and enhance overall user experience. The multi-center, prospective trial will study the next-generation CGM sensor in up to 460 participants with type 1 or type 2 diabetes aged two to 80 years old over the course of seven days. Study participants will be randomly assigned to sensor wear location and testing days and times.
- GlobeNewswire•7 days ago
Medtronic and Tidepool Work Together on Interoperable Automated Insulin Pump System for Diabetes Management
June 7, 2019 - Medtronic plc (MDT), the global leader in medical technology, services and solutions, and Tidepool, a 501(c)(3) nonprofit organization dedicated to making diabetes data more accessible, actionable and meaningful, have agreed to work together to create an interoperable automated insulin pump system. Medtronic will develop a future Bluetooth-enabled MiniMed(TM) pump that would be compatible with Tidepool Loop, a future FDA-regulated, open source automated insulin delivery app for iPhone® and Apple Watch® currently in development. "We think that Medtronic is making a very bold and important move here that shows tremendous courage and is the absolutely right thing for the diabetes community," said Howard Look, founder and CEO of Tidepool.
- Zacks•16 days ago
Medtronic Receives FDA Nod for SelectSite Catheter System
The launch of the SelectSite catheter is in line with Medtronic's (MDT) goal to expand its cardiac care portfolio.
- GlobeNewswire•17 days ago
Medtronic Chairman and CEO Omar Ishrak to Speak at Goldman Sachs Global Healthcare Conference
May 29, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced that it will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019, in Rancho Palos Verdes, California. Omar Ishrak, Medtronic chairman and chief executive officer, will answer questions about the company beginning at 11:20 a.m. PDT (1:20 p.m. CDT). Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world`s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
- GlobeNewswire•17 days ago
Medtronic Gains U.S. FDA Clearance for New Catheter System for HIS Bundle Pacing
May 29, 2019 - Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) clearance and commercial launch for the SelectSite(TM) C304-HIS deflectable catheter system for use in procedures involving His-bundle pacing (HBP). The SelectSite C304-HIS deflectable catheter system features a deflectable, out-of-plane curve to reach the bundle of His and is designed to enable enhanced range maneuverability, fixation and implant success for a wider range of patient anatomies. The new catheter system facilitates placement of the Medtronic SelectSecure(TM) MRI SureScan(TM) Model 3830 cardiac pacing lead, the only pacing lead on the U.S. market approved for HBP.
- Market Realist•17 days ago
What Is Medtronic Guiding for Its Business Segments in 2020?
Is Medtronic an Attractive Pick after Its Q4 Results?(Continued from Prior Part)Revenue growth guidanceOn its fourth-quarter earnings conference call, Medtronic (MDT) guided for YoY (year-over-year) organic revenue growth of 4.5%–5% for its
- Barrons.com•17 days ago
3 Dividend Stock Picks From an Income Fund Manager
Phil Davidson, a longtime co-manager of the American Century Equity Income Fund, notes that the highest-yielding stocks haven’t performed all that well in recent years.
- GlobeNewswire•18 days ago
Medtronic EVP & CVG President Mike Coyle to Speak at Jefferies 2019 Global Healthcare Conference
May 28, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced it will participate in the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019, in New York City. Mike Coyle, executive vice president and president of Medtronic`s Cardiac and Vascular group (CVG), will answer questions about the company beginning at 11:00 a.m. EDT (10:00 a.m. CDT). A live audio webcast of the session will be available on June 5, 2019, by clicking on the Investors Events link at http://investorrelations.medtronic.com. An archived audio file will be available for replay on the same webpage later in the day.
Market Realist•18 days agoEmerging Markets: Medtronic’s Key Revenue Driver in 2019
Is Medtronic an Attractive Pick after Its Q4 Results?(Continued from Prior Part)Revenue performance by geographyIn the fourth quarter, Medtronic (MDT) earned revenue of $4.28 billion in the US market, a YoY (year-over-year) rise of 2.3% on a
- Zacks•18 days ago
The Zacks Analyst Blog Highlights: Medtronic, TJX, Deere, Incyte and Netapp
The Zacks Analyst Blog Highlights: Medtronic, TJX, Deere, Incyte and Netapp
- GlobeNewswire•18 days ago
MiniMed(TM) 670G System Real-World Data on 8 Million Patient Days Shows 71 Percent Time in Range Across All Age Groups
May 28, 2018 - Medtronic plc (MDT), the global leader in medical technology, today announced real-world clinical outcomes for the MiniMed(TM) 670G system, which is being used by more than 180,000 people today. The advanced algorithm in the MiniMed 670G system automates and personalizes the delivery of basal insulin 24 hours a day and is the only commercially available technology in the world that proactively drives increased Time in Range by consistently guiding to the target of 120 mg/dL throughout the day-the lowest range offered in an automated insulin pump system. See animation to understand how the MiniMed 670G system works.
Market Realist•18 days agoMedtronic Guides for Robust Free Cash Flow Conversion for 2020
Is Medtronic an Attractive Pick after Its Q4 Results?(Continued from Prior Part)Free cash flow targetDuring its 2018 Investor Day presentation, Medtronic (MDT) set a target of 80% FCF (free cash flow) conversion to be attained within the next two to
- Market Realist•18 days ago
Medtronic Has Guided for Modest Margin Expansion in 2020
Is Medtronic an Attractive Pick after Its Q4 Results?(Continued from Prior Part)Operating margin performance and guidanceIn the fourth quarter, Medtronic (MDT) reported a non-GAAP (generally accepted accounting principles) operating margin of 31.5%,
Market Realist•19 days agoMedtronic Has Guided for a Robust EPS Performance in 2020
Is Medtronic an Attractive Pick after Its Q4 Results?(Continued from Prior Part)EPS guidanceIn its fiscal 2019 fourth-quarter earnings investor presentation, Medtronic (MDT) guided for non-GAAP (generally accepted accounting principles) EPS of
- Market Realist•19 days ago
What Analysts Recommend for Medtronic after Its Q4 Results
Is Medtronic an Attractive Pick after Its Q4 Results?Stock price movementsOn May 23, Medtronic (MDT) reported its fiscal 2019 fourth-quarter earnings results. The company reported revenue of $8.15 billion in the quarter, a YoY (year-over-year) rise
- GlobeNewswire•22 days ago
Medtronic Chairman and CEO Omar Ishrak to Speak at Bernstein Strategic Decisions Conference
May 24, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced that it will participate in the Bernstein 35th Annual Strategic Decisions Conference on Wednesday, May 29, 2019, in New York City. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a presentation and will answer questions about the company beginning at 10:00 a.m. EDT (9:00 a.m. CDT). Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world`s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
- Zacks•22 days ago
Top Stock Reports for Medtronic, TJX Companies & Deere
Top Stock Reports for Medtronic, TJX Companies & Deere
- Motley Fool•23 days ago
What Happened in the Stock Market Today
Trade worries hit the market, with Best Buy falling despite a good quarter and Medtronic rising on strong profit.
Motley Fool•23 days agoMedtronic (MDT) Q3 2019 Earnings Call Transcript
MDT earnings call for the period ending March 31, 2019.
- Motley Fool•23 days ago
Medtronic PLC (MDT) Q4 2019 Earnings Call Transcript
MDT earnings call for the period ending April 26, 2019.
